Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning Province 110016, PR China.
Department of Microbial and Biochemical Pharmacy, School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning Province 110016, PR China.
J Colloid Interface Sci. 2025 Jan 15;678(Pt A):378-392. doi: 10.1016/j.jcis.2024.08.172. Epub 2024 Aug 24.
Combination therapies have attracted significant attention because they address the limitations of monotherapy while improving overall efficacy. In this study, we designed a novel nanoplatform, named GOx@Fe-DMSN@PDA (GFDP), by integrating Fe into dendritic mesoporous silica nanoparticles (DMSN) and selecting glucose oxidase (GOx) as the model drug loaded into the DMSN pores. Additionally, we coated the surface of the DMSN with polydopamine (PDA) to confer pH/near infrared (NIR) light-responsive controlled-release behavior and photothermal therapy (PTT). The introduction of Fe into the DMSN framework greatly improved biodegradability and enhanced the peroxidase (POD)-like activity of GFDP. In addition, GOx could consume glucose and generate hydrogen peroxide (HO) within tumor cells to facilitate starvation therapy and enhance cascade catalysis. The PDA coating provided the DMSN with an intelligent response release ability, promoting efficient photothermal conversion and achieving the PTT effect. Cellular tests showed that under NIR light irradiation, GFDP exhibited a synergistic effect of PTT-enhanced starvation therapy and cascade catalysis, with a half-maximal inhibitory concentration (IC) of 2.89 μg/mL, which was significantly lower than that of GFDP without NIR light irradiation (18.29 μg/mL). The in vivo anti-tumor effect indicated that GFDP could effectively accumulate at the tumor site for thermal imaging and showed remarkable synergistic therapeutic effects. In summary, GFDP is a promising nanoplatform for multi-modal combination therapy that integrates starvation therapy, PTT, and cascade catalysis.
联合治疗引起了广泛关注,因为它解决了单药治疗的局限性,同时提高了整体疗效。在本研究中,我们设计了一种新型纳米平台,命名为 GOx@Fe-DMSN@PDA(GFDP),通过将 Fe 整合到树枝状介孔硅纳米颗粒(DMSN)中,并选择葡萄糖氧化酶(GOx)作为负载到 DMSN 孔中的模型药物。此外,我们在 DMSN 表面包覆聚多巴胺(PDA),赋予其 pH/近红外(NIR)光响应控制释放行为和光热治疗(PTT)。Fe 的引入极大地提高了 DMSN 的生物降解性,并增强了 GFDP 的过氧化物酶(POD)样活性。此外,GOx 可以在肿瘤细胞内消耗葡萄糖并产生过氧化氢(HO),以促进饥饿治疗并增强级联催化。PDA 涂层为 DMSN 提供了智能响应释放能力,促进了高效的光热转换并实现了 PTT 效应。细胞试验表明,在近红外光照射下,GFDP 表现出 PTT 增强饥饿治疗和级联催化的协同效应,半抑制浓度(IC)为 2.89μg/mL,明显低于无近红外光照射的 GFDP(18.29μg/mL)。体内抗肿瘤效果表明,GFDP 能够有效地在肿瘤部位聚集进行热成像,并表现出显著的协同治疗效果。综上所述,GFDP 是一种有前途的多模式联合治疗纳米平台,整合了饥饿治疗、PTT 和级联催化。